+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Therapeutic Drug Monitoring Consumables Market - Global Forecast to 2030- Product Image
Therapeutic Drug Monitoring Consumables Market - Global Forecast to 2030- Product Image
New

Therapeutic Drug Monitoring Consumables Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6080465
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
In the evolving landscape of therapeutic drug monitoring (TDM), consumables play a critical role in ensuring accurate dosage optimization, patient safety, and treatment efficacy. This executive summary distills key developments shaping the market for TDM consumables, presenting strategic insights into current dynamics and emerging opportunities. As healthcare systems worldwide confront the dual challenges of personalized medicine and cost containment, robust monitoring solutions have become indispensable. Consumables-ranging from assay kits and reagents to calibrated quality control materials-work in tandem with consultation and testing services to deliver comprehensive diagnostic workflows. Stakeholders across pharmaceutical, clinical, and research domains increasingly demand reliable, high-throughput platforms capable of integrating seamlessly into laboratory operations. This introduction sets the stage for a deeper exploration of transformative shifts, tariff impacts, segmentation nuances, regional variations, competitive landscapes, and actionable recommendations designed to guide decision-makers toward informed investments and sustainable growth.

Transformative Shifts Redefining the Therapeutic Drug Monitoring Landscape

Recent years have witnessed a profound transformation in the TDM consumables domain, driven by technological, regulatory, and market forces. Automation has accelerated assay throughput, reducing manual intervention and minimizing variability, while digital platforms have enhanced data capture and analytics, enabling predictive dosing algorithms. Simultaneously, advancements in mass spectrometry and high-performance liquid chromatography have broadened the spectrum of measurable analytes, from narrow-therapeutic-index drugs to emerging biologics. Regulatory agencies worldwide are placing greater emphasis on standardized quality control practices and traceability, prompting manufacturers to refine calibrator and QC material offerings. Patient-centric care models have encouraged decentralized testing, fostering demand for point-of-care immunoassays and compact chromatographic solutions. Furthermore, the convergence of service and consumable providers into integrated partnerships is reshaping traditional business models, as end users seek turnkey solutions that streamline procurement and technical support. These shifts collectively underscore a maturation of the market, wherein agility, interoperability, and compliance define competitive advantage.

Cumulative Impact of United States Tariffs 2025 on Supply Chains and Pricing

The introduction of revised United States tariffs in 2025 has exerted a cumulative impact on TDM consumables, reverberating throughout global supply chains and pricing structures. Import duties on kits, reagents, and specialized instrumentation components have elevated landed costs, prompting some distributors to adjust pricing tiers for end users. Manufacturers sourcing raw materials internationally have confronted heightened expenditures, necessitating cost-containment strategies such as localized procurement or dual-sourcing agreements. The ripple effect extends to quality control materials, where calibrators and multi-use reagents may experience longer lead times as suppliers realign production footprints to mitigate tariff burdens. Simultaneously, service providers offering consultation and testing are recalibrating service fees to account for increased operational outlays. To preserve market accessibility, some market participants are exploring zone-based warehousing solutions, optimizing duty deferral schemes, and leveraging free trade agreements. This tariff environment underscores the need for proactive supply chain resilience, transparent cost modeling, and collaborative dialogue among manufacturers, distributors, and regulatory bodies.

Key Segmentation Insights Across Product, Therapeutic Area, End User, Test Type, and Application

A nuanced understanding of market segmentation illuminates the diverse drivers of demand and identifies high-potential niches within the TDM consumables arena. Based on product type, the market bifurcates into consumables and services, where consumables encompass kits and reagents. Kits focus primarily on assay kits while reagents subdivide into calibrators and quality control materials. Calibrators differentiate into multi-use calibrators and single-use calibrators, whereas quality control materials divide between externally provided QC materials and in-house QC materials. Services span consultation services and testing services, offering analytic interpretation and laboratory workflow integration. Based on therapeutic area, TDM applications address cardiology, infectious disease, and oncology, with cardiology targeting cardiac arrhythmias and heart failure, infectious disease centering on HIV management, and oncology covering breast cancer and lung cancer. Based on end user, consumption originates from academic and research institutes, clinical laboratories-comprising hospital-based laboratories and independent laboratories-hospitals, including private hospitals and public hospitals, and pharmaceutical companies engaged in drug development and clinical trials. Based on test type, methodologies include chromatography-based tests, exemplified by high-performance liquid chromatography; immunoassays, featuring enzyme-linked immunosorbent assay with direct ELISA and indirect ELISA as well as radioimmunoassays; and mass spectrometry-based tests such as gas chromatography-mass spectrometry. Based on application, emphasis falls on drug monitoring and pharmacokinetics, with core protocols for cyclosporine monitoring and tacrolimus monitoring delivering precise therapeutic window management. This segmentation framework reveals opportunities for targeted innovation, custom reagent formulation, and specialized service bundles tailored to distinct clinical and research settings.

Key Regional Insights Highlighting Americas, EMEA, and Asia-Pacific Dynamics

Regional market dynamics reveal distinct growth trajectories and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, robust healthcare infrastructure, comprehensive reimbursement frameworks, and early adoption of advanced diagnostic technologies drive sustained demand for high-throughput assay kits and integrated QC solutions. Consolidation among leading clinical laboratory networks further amplifies procurement volumes and enhances bargaining power. In Europe, regulatory harmonization efforts under IVDR create a unified compliance environment, encouraging pan-regional distribution of standardized calibrators and assay kits. Meanwhile, the Middle East & Africa region exhibits selective adoption, with major urban centers investing in centralized testing hubs, albeit tempered by supply chain complexities. The Asia-Pacific region emerges as the fastest growing market, propelled by expanding pharmaceutical R&D, increasing prevalence of chronic diseases, and rising public-private collaborations to bolster hospital-based laboratories and academic research facilities. Government initiatives supporting biotechnology innovation and favorable tax incentives for local manufacturing bolster the regional ecosystem. Collectively, these regional insights inform tailored go-to-market strategies, strategic alliance formation, and localization efforts essential for sustainable expansion.

Key Companies Driving Innovation and Competitive Landscape in TDM Consumables

The competitive landscape features a mix of established conglomerates and specialized innovators shaping the trajectory of the TDM consumables market. Abbott Laboratories leads with a comprehensive portfolio of immunoassays and automated analyzers, driving adoption through robust service networks. Agilent Technologies, Inc. focuses on advanced liquid chromatography and mass spectrometry platforms, enhancing analytical sensitivity for low-concentration drug quantitation. ARK Diagnostics, Inc. differentiates with niche assay kits designed for rapid point-of-care monitoring. Bio-Rad Laboratories, Inc. leverages its expertise in quality control materials to offer validated calibration solutions. Biomérieux S.A integrates molecular diagnostics with TDM offerings, enabling multiplexed workflows. Danaher Corporation advances test automation and digital data management through strategic acquisitions. HealthTronics, Inc. provides consultation services tailored to laboratory accreditation and workflow optimization. Hoffmann-La Roche Ltd (Roche) capitalizes on immunochemistry platforms to support oncology and cardiology monitoring. Invitrogen Corporation, under Thermo Fisher Scientific Inc., expands reagent portfolios with customizable assays. Nephron Pharmaceuticals Corporation specializes in immunosuppressant monitoring kits. PerkinElmer, Inc. develops high-efficient chromatography consumables. Randox Laboratories Ltd innovates biochip diagnostics for multiplex drug panels. Siemens Healthineers AG integrates system-wide connectivity for end-to-end solutions. Theranostics Laboratory Pvt. Ltd. pioneers regionally optimized assay protocols. Thermo Fisher Scientific Inc. underpins large-scale operations with global supply chain resilience and comprehensive QC offerings. These leading companies invest heavily in R&D, strategic partnerships, and digital integration to address evolving user requirements and maintain competitive differentiation.

Actionable Recommendations for Industry Leaders to Capitalize on Market Opportunities

To capitalize on the dynamic market environment, industry leaders should prioritize several actionable strategies. First, intensify investment in R&D to advance next-generation reagents and assay kits that accommodate novel therapeutic molecules, including biologics and small molecules with narrow therapeutic indices. Second, forge strategic partnerships with clinical laboratories, academic institutions, and pharmaceutical developers to co-create customized service and consumable bundles that address specific workflow challenges. Third, establish supply chain resilience by diversifying raw material sourcing, leveraging free trade zones, and optimizing inventory management to mitigate tariff impacts and geopolitical disruptions. Fourth, integrate digital platforms for real-time data analytics and remote monitoring, enabling predictive maintenance of assay systems and personalized risk stratification. Fifth, engage proactively with regulatory bodies to shape policy frameworks and ensure accelerated approval pathways for innovative QC materials. Sixth, expand geographic footprint through localized manufacturing or joint ventures in high-growth markets, particularly within Asia-Pacific and targeted EMEA clusters. Seventh, develop integrated training and certification programs to upskill end-users and reinforce product adoption. Lastly, commit to sustainable practices by reducing single-use plastic in consumables and implementing eco-friendly packaging solutions, meeting evolving environmental standards and reinforcing corporate responsibility.

Conclusion Summarizing Key Insights and Strategic Imperatives

In summary, the therapeutic drug monitoring consumables market stands at a pivotal juncture, influenced by technological innovation, regulatory evolution, and shifting regional dynamics. The segmentation framework underscores the heterogeneity of demand across product types, therapeutic areas, end users, test methodologies, and applications, guiding focused development and market penetration strategies. Tariff adjustments in the United States highlight the urgency of supply chain adaptability and transparent pricing models. Key regional insights emphasize differentiated approaches for the Americas, EMEA, and Asia-Pacific, while the competitive landscape illustrates the diverse strengths of leading players. By implementing targeted recommendations-ranging from R&D acceleration and digital integration to partnership cultivation and sustainability commitments-stakeholders can navigate complexity, capture emerging opportunities, and deliver enhanced patient outcomes. This conclusion reinforces the imperative for agile decision-making and strategic foresight in an increasingly competitive environment.

Market Segmentation & Coverage

This research report categorizes the Therapeutic Drug Monitoring Consumables Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Consumables
    • Kits
      • Assay Kits
    • Reagents
      • Calibrators
        • Multi Use Calibrators
        • Single Use Calibrators
      • Quality Control Materials
        • Externally Provided QC Materials
        • In-House QC Materials
  • Services
    • Consultation Services
    • Testing Services
  • Cardiology
    • Cardiac Arrhythmias
    • Heart Failure
  • Infectious Disease
    • HIV
  • Oncology
    • Breast Cancer
    • Lung Cancer
  • Academic & Research Institutes
  • Clinical Laboratories
    • Hospital-Based Laboratories
    • Independent Laboratories
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Pharmaceutical Companies
  • Chromatography-Based Tests
    • High-Performance Liquid Chromatography
  • Immunoassays
    • Enzyme-Linked Immunosorbent Assay
      • Direct ELISA
      • Indirect ELISA
    • Radioimmunoassays
  • Mass Spectrometry-Based Tests
    • Gas Chromatography-Mass Spectrometry
  • Drug Monitoring
    • Cyclosporine Monitoring
    • Tacrolimus Monitoring
  • Pharmacokinetics

This research report categorizes the Therapeutic Drug Monitoring Consumables Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Therapeutic Drug Monitoring Consumables Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ARK Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Biomérieux S.A
  • Danaher Corporation
  • HealthTronics, Inc.
  • Hoffmann-La Roche Ltd (Roche)
  • Invitrogen Corporation
  • Nephron Pharmaceuticals Corporation
  • PerkinElmer, Inc.
  • Randox Laboratories Ltd
  • Siemens Healthineers AG
  • Theranostics Laboratory Pvt. Ltd.
  • Thermo Fisher Scientific Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Therapeutic Drug Monitoring Consumables Market, by Product Type
8.1. Introduction
8.2. Consumables
8.2.1. Kits
8.2.1.1. Assay Kits
8.2.2. Reagents
8.2.2.1. Calibrators
8.2.2.1.1. Multi Use Calibrators
8.2.2.1.2. Single Use Calibrators
8.2.2.2. Quality Control Materials
8.2.2.2.1. Externally Provided QC Materials
8.2.2.2.2. In-House QC Materials
8.3. Services
8.3.1. Consultation Services
8.3.2. Testing Services
9. Therapeutic Drug Monitoring Consumables Market, by Therapeutic Area
9.1. Introduction
9.2. Cardiology
9.2.1. Cardiac Arrhythmias
9.2.2. Heart Failure
9.3. Infectious Disease
9.3.1. HIV
9.4. Oncology
9.4.1. Breast Cancer
9.4.2. Lung Cancer
10. Therapeutic Drug Monitoring Consumables Market, by End User
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Clinical Laboratories
10.3.1. Hospital-Based Laboratories
10.3.2. Independent Laboratories
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
10.5. Pharmaceutical Companies
11. Therapeutic Drug Monitoring Consumables Market, by Test Type
11.1. Introduction
11.2. Chromatography-Based Tests
11.2.1. High-Performance Liquid Chromatography
11.3. Immunoassays
11.3.1. Enzyme-Linked Immunosorbent Assay
11.3.1.1. Direct ELISA
11.3.1.2. Indirect ELISA
11.3.2. Radioimmunoassays
11.4. Mass Spectrometry-Based Tests
11.4.1. Gas Chromatography-Mass Spectrometry
12. Therapeutic Drug Monitoring Consumables Market, by Application
12.1. Introduction
12.2. Drug Monitoring
12.2.1. Cyclosporine Monitoring
12.2.2. Tacrolimus Monitoring
12.3. Pharmacokinetics
13. Americas Therapeutic Drug Monitoring Consumables Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Therapeutic Drug Monitoring Consumables Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Therapeutic Drug Monitoring Consumables Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. Agilent Technologies, Inc.
16.3.3. ARK Diagnostics, Inc.
16.3.4. Bio-Rad Laboratories, Inc.
16.3.5. Biomérieux S.A
16.3.6. Danaher Corporation
16.3.7. HealthTronics, Inc.
16.3.8. Hoffmann-La Roche Ltd (Roche)
16.3.9. Invitrogen Corporation
16.3.10. Nephron Pharmaceuticals Corporation
16.3.11. PerkinElmer, Inc.
16.3.12. Randox Laboratories Ltd
16.3.13. Siemens Healthineers AG
16.3.14. Theranostics Laboratory Pvt. Ltd.
16.3.15. Thermo Fisher Scientific Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET MULTI-CURRENCY
FIGURE 2. THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET MULTI-LANGUAGE
FIGURE 3. THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MULTI USE CALIBRATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SINGLE USE CALIBRATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY EXTERNALLY PROVIDED QC MATERIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IN-HOUSE QC MATERIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TESTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIAC ARRHYTHMIAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DIRECT ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY RADIOIMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CYCLOSPORINE MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TACROLIMUS MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PHARMACOKINETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 133. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 135. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 136. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 137. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 138. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 139. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 140. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 141. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 142. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 143. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 144. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 146. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 147. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 148. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 149. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 150. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 151. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 152. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. CANADA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 154. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 156. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 157. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 158. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 161. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 162. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 163. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 164. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 165. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 167. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 168. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 169. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 172. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. MEXICO THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 240. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 242. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 243. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 244. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 245. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 246. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 247. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 248. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 249. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 250. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 251. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 253. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 254. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 255. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 256. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 257. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 258. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 259. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. CHINA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY DRUG MONITORING, 2018-2030 (USD MILLION)
TABLE 261. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 263. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 264. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 265. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CALIBRATORS, 2018-2030 (USD MILLION)
TABLE 266. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY QUALITY CONTROL MATERIALS, 2018-2030 (USD MILLION)
TABLE 267. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 268. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 269. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 270. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 271. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 272. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 274. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 275. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 276. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY CHROMATOGRAPHY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 277. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 278. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 279. INDIA THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET SIZE, BY MASS SPECTROMETRY-BASED TESTS, 2018-2030 (USD MILLION)
TABLE 280. INDIA THERAPEUTIC DRUG MONITORING C

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ARK Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Biomérieux S.A
  • Danaher Corporation
  • HealthTronics, Inc.
  • Hoffmann-La Roche Ltd (Roche)
  • Invitrogen Corporation
  • Nephron Pharmaceuticals Corporation
  • PerkinElmer, Inc.
  • Randox Laboratories Ltd
  • Siemens Healthineers AG
  • Theranostics Laboratory Pvt. Ltd.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Therapeutic Drug Monitoring Market Size, Share & Trends Analysis Report By Product (Equipment, Consumables), By Drug Class (Antiarrhythmic Drugs), By End Use (Diagnostic Centers), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Therapeutic Drug Monitoring Market Size, Share & Trends Analysis Report By Product (Equipment, Consumables), By Drug Class (Antiarrhythmic Drugs), By End Use (Diagnostic Centers), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Therapeutic Drug Monitoring Market by Product, Technology, Drug Class, Therapeutic Area, Specimen, End User - Global Forecast to 2029 - Product Image

Therapeutic Drug Monitoring Market by Product, Technology, Drug Class, Therapeutic Area, Specimen, End User - Global Forecast to 2029

  • Report
  • 381 Pages
  • Global
From
Therapeutic Drug Monitoring Market Report 2025 - Product Image

Therapeutic Drug Monitoring Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Therapeutic Drug Monitoring - Global Strategic Business Report - Product Image

Therapeutic Drug Monitoring - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Drug Simulation Research & Development Platform Market - Global Forecast to 2030 - Product Image

Drug Simulation Research & Development Platform Market - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global, United States Global, United States
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.